Oxford BioDynamics (LON:OBD) Issues Quarterly Earnings Results

Oxford BioDynamics (LON:OBD) posted its earnings results on Tuesday. The biotechnology company reported GBX (0.10) earnings per share for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative return on equity of 316.67% and a negative net margin of 1,018.54%.

Oxford BioDynamics Stock Down 5.3%

Shares of OBD traded down GBX 0.01 on Thursday, hitting GBX 0.09. The company’s stock had a trading volume of 56,582,594 shares, compared to its average volume of 16,605,920. The company has a quick ratio of 2.80, a current ratio of 0.88 and a debt-to-equity ratio of 457.97. The firm’s fifty day moving average price is GBX 0.18 and its 200-day moving average price is GBX 0.23. Oxford BioDynamics has a fifty-two week low of GBX 0.08 and a fifty-two week high of GBX 0.78. The firm has a market capitalization of £3.86 million, a price-to-earnings ratio of -0.11 and a beta of 0.42.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.